Search results
Found 122 matches for
An internationally recognised centre of excellence for biomedical and clinical research and teaching
Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme
Awards and Appointments General Innovation
11 October 2021
The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.
Anti-cancer drug derived from fungus shows promise in clinical trials
Clinical Trials General Innovation Research
7 October 2021
A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
Oxford BioEscalator celebrates three years of innovation
General Innovation
13 September 2021
The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.
Immunology and AI drug discovery partnership agreed with Sensyne Health
General Innovation Research
25 August 2021
The University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks and his team at the Nuffield Department of Medicine’s Respiratory Medicine Unit.
Oxford overseas research facility expands to include diagnostics and genetics testing centre
General Innovation
12 July 2021
The Oxford-Suzhou Centre for Advanced Research, known as OSCAR, has marked another significant milestone with the launch of OSCAR-Prenetics Innovation and Technology Centre for Advanced Molecular Diagnostics (the OSCAR-Prenetics ITC).
Oxford joins forces with 11 universities to launch social impact investment fund
General Innovation
23 June 2021
The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.
AIMday in Experimental Medicine in Psychiatry - registration for academics now open
Events Innovation
1 June 2021
Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Experimental Medicine in Psychiatry.
Innovation award for Professor Anindita Roy to develop new treatments for childhood cancer
Awards and Appointments General Innovation Research
18 March 2021
Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.
Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal
Awards and Appointments Coronavirus COVID-19 General Innovation Research
5 March 2021
Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.
Singula Bio, a new Oxford spin-out company - Cancer need not be fatal
General Innovation Research
25 February 2021
Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.
Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders
General Innovation
16 February 2021
The University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
BioEscalator’s Enara Bio partners with Boehringer Ingelheim to develop novel cancer immunotherapies
General Innovation
4 February 2021
Enara Bio, a start-up located in the University’s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over €876M (£787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.
Investigating New Treatment for Schizophrenia
General Innovation Research
21 January 2021
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
£100 million donation from Ineos to create new institute to fight antimicrobial resistance
Awards and Appointments General Innovation
19 January 2021
A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.
University spinout PepGen awarded major financing to target Duchenne muscular dystrophy
Awards and Appointments General Innovation
9 December 2020
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships
Awards and Appointments General Innovation
9 December 2020
Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced today*. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.
Evox Therapeutics announces launch of strategic collaboration with the University of Oxford
General Innovation
18 November 2020
Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases
BioEscalator’s resident biotech Base Genomics acquired by Exact Sciences
General Innovation
4 November 2020
Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.
Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium
Coronavirus COVID-19 Innovation Research
29 October 2020
Comparison of five tests used to detect COVID-19 antibodies shows Siemens and Oxford assays met regulatory targets
Coronavirus COVID-19 Innovation Research
28 September 2020
New research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as ‘immunoassays’), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.